Jyong Biotech Ltd. (MENS)

Market Cap	168.51M -96.3%
Revenue (ttm)	n/a
Net Income	-4.67M
EPS	-0.06
Shares Out	74.23M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	40,359
Open	2.320
Previous Close	2.250
Day's Range	2.210 - 2.410
52-Week Range	1.430 - 67.000
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	May 15, 2026

About MENS

Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome. The company was founded in 2002 and is headquartered in New Taipei City, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 17, 2025
• Employees: 27
• Stock Exchange: NASDAQ
• Ticker Symbol: MENS
• Website: https://jyongbio.com

Financial Performance

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Sep 4, 2026

Data Sources Report a data error